What is the efficacy of transfusions or hydroxycarbamide for the prevention of stroke in patients with sickle cell disease (SCD)?

Updated: May 12, 2021
  • Author: Joseph E Maakaron, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

In TWiTCH, no strokes were identified in patients treated with either transfusions (n=61) hydroxycarbamide (n=60), but three transient ischemic attacks occurred in each group.  TCD velocities were 143 cm/s in children who received transfusions and 138 cm/s in those who received hydroxycarbamide. [101]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!